Literature DB >> 21342309

Preoperative expectations and values of patients undergoing Mohs micrographic surgery.

Gary S Chuang1, Brian C Leach, Lee Wheless, Pearon G Lang, Joel Cook.   

Abstract

BACKGROUND: Dermatologists have championed Mohs micrographic surgery (MMS) for its unsurpassed treatment success for skin cancers, safety profile, cost-effectiveness, and tissue-sparing quality. It is unclear whether patients undergoing MMS also value these characteristics.
OBJECTIVE: To evaluate patients' preoperative expectations of MMS and identify the factors that may influence such expectations
METHODS: The study prospectively recruited participants who were newly diagnosed with skin cancer and referred for MMS. A questionnaire listing the characteristics of MMS was given to the participants asking them to score the importance of each characteristic on a 10-point scale. The participants were also asked to provide information regarding their gender, age, subjective health status, education level, family annual income, and their referral source
RESULTS: On average, participants placed the highest value, in descending order, on a treatment that yielded the highest cure rate, reconstruction initiation only after complete tumor removal, and the surgeon being a skin cancer specialist. Overall, participants placed high values on characteristics of MMS that dermatologists have long esteemed.
CONCLUSION: Our data corroborate that MMS is a valuable procedure that meets the expectations not just of physicians, but also of patients. The authors have indicated no significant interest with commercial supporters.
© 2011 by the American Society for Dermatologic Surgery, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21342309     DOI: 10.1111/j.1524-4725.2011.01878.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  1 in total

1.  Correlation Between Appropriate Use Criteria and the Frequency of Subclinical Spread or Reconstruction With a Flap or Graft for Melanomas Treated With Mohs Surgery With Melanoma Antigen Recognized by T Cells 1 Immunostaining.

Authors:  Jeremy R Etzkorn; Joseph F Sobanko; Thuzar M Shin; Rosalie Elenitsas; Emily Y Chu; Joel M Gelfand; David J Margolis; Jason G Newman; Hayley Goldbach; Christopher J Miller
Journal:  Dermatol Surg       Date:  2016-04       Impact factor: 3.398

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.